RxDoctor Payments Data

Michael Principe, DO

Orthopaedic Surgery · Wilmington, DENPI 1760661193

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $24,300 of the $29,119 with a category attached, or 83.4%. 15 manufacturers reported payments, led by Medical Device Business Services, Inc. at 45.1% of the total. Reporting peaked in 2020 at $13,445 and has fallen 64.4% since, to $4,784 in 2025.

$29,119in general payments, 2019–2025

Across 83 payments — averaging $350.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$13K
  • Synthes USA Products LLC$12K
  • Liberty Surgical Inc.$1K
  • Arthrex$1K
  • Stryker$988
  • Johnson & Johnson$193
  • plus $546 from 9 others

What the payments were for

  • Consulting fees$24,30083%
  • Speaking & faculty fees$1,0003%
  • Travel & lodging$2901%
  • Food & beverage$2,3308%
  • Education$1,2004%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,119 in reported general payments places this provider in the 80th percentile of 70 orthopaedic surgery providers in Delaware.

See all orthopaedic surgery providers in Delaware

Medicare billing

Part B allowed, 2024
$210,874
Medicare patients
262
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin22$362
Meloxicam18$72
Tramadol Hcl26$61

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →